China Oncology ›› 2015, Vol. 25 ›› Issue (3): 231-234.doi: 10.3969/j.issn.1007-3969.2015.03.012

Previous Articles     Next Articles

Clinical advancement of hypercoagulability in patients with ovarian cancer

FENG Zheng, WEN Hao, WU Xiaohua   

  1. Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2015-03-30 Published:2015-05-18
  • Contact: WU Xiaohua E-mail:

Abstract:      The incidence of venous thromboembolism in patients with ovarian cancer is much higher than other gynecologic cancers. Approximate 20% of ovarian cancer patients have hypercoagulable status during different phases of their disease. Ovarian cancer itself can induce hypercoagulability, but meanwhile the over activated coagulation system may promote disease progression. Coagulation system disorder is one of the most important prognostic factors in ovarian cancer. Recently, hypercoagulability becomes a hot spot in the ovarian cancer research field. This article reviews the mechanism of hypercoagulability, its clinical implication and correlated treatment in ovarian cancer patients.

Key words: Ovarian cancer, Hypercoagulability, Interleukin-6